Experimental cancer drug KD033 tested in early trial – but study halted

NCT ID NCT04242147

Terminated Disease control Sponsor: Kadmon, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study tested an experimental drug called KD033 (SAR445710) in 45 adults with advanced or metastatic solid tumors. The main goal was to check safety and find the right dose, while also looking for any anti-cancer effects. The trial was terminated, so final results may be limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KD033 (SAR445710)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors.
What could go wrong: This is a very early Phase 1 trial, so safety and effectiveness are not yet proven. The study was terminated, meaning results may be limited or inconclusive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Fox Chase Cancer Center - 333 Cottman Avenue - Site 141

Philadelphia, Pennsylvania, 19111, United States
Moffitt Cancer Center - Site 102

Tampa, Florida, 33612, United States
Roswell Park Cancer Institute - 665 Elm St - Site 062

Buffalo, New York, 14263, United States
UCLA Hematology/Oncology, 2020 Santa Monica Boulevard, Suite 600 - Site 042

Santa Monica, California, 90404, United States
University of Pittsburgh Medical Center - Hillman Cancer Center - 5150 Centre Avenue, Suite 301 - Site 132

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.